- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06672939
En undersøgelse af Orforglipron (LY3502970) hos unge deltagere med fedme eller overvægt med relaterede komorbiditeter
Effekt, sikkerhed og farmakokinetik af Orforglipron én gang dagligt oralt versus placebo hos unge deltagere, der har fedme eller overvægtige med vægtrelaterede komorbiditeter: Et randomiseret, dobbeltblindt forsøg (ADVANCE-ATAIN-ADOLESCENTS)
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months.
Participants who have completed the primary PW01 study (including the 4-week safety follow-up period) will have the opportunity to receive an additional 156 weeks of treatment with orforglipron as well as continuing the lifestyle intervention.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Telefonnummer: 1-317-615-4559
- E-mail: LillyTrials@Lilly.com
Undersøgelse Kontakt Backup
- Navn: Physicians interested in becoming principal investigators please contact
- E-mail: clinical_inquiry_hub@lilly.com
Studiesteder
-
-
-
Barnsley, Det Forenede Kongerige, S75 2EP
- Aktiv, ikke rekrutterende
- Barnsley Hospital NHS Foundation Trust
-
Dundee, Det Forenede Kongerige, DD1 9SY
- Ikke rekrutterer endnu
- Ninewells Hospital
-
Ledende efterforsker:
- Nicholas Conway
-
Kontakt:
- Telefonnummer: (44138) 238-8385
-
Hull, Det Forenede Kongerige, HU3 2JZ
- Aktiv, ikke rekrutterende
- Hull Royal Infirmary
-
-
-
-
California
-
Oxnard, California, Forenede Stater, 93030
- Aktiv, ikke rekrutterende
- Carey Chronis MD Pediatric, Infant and Adolescent Medicine
-
-
Connecticut
-
Stamford, Connecticut, Forenede Stater, 06905
- Aktiv, ikke rekrutterende
- Stamford Therapeutics Consortium
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30329
- Aktiv, ikke rekrutterende
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Aktiv, ikke rekrutterende
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Louisiana
-
Lafayette, Louisiana, Forenede Stater, 70508
- Aktiv, ikke rekrutterende
- Velocity Clinical Research
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63141-7068
- Aktiv, ikke rekrutterende
- Sundance Clinical Research
-
-
North Carolina
-
Morehead City, North Carolina, Forenede Stater, 28557
- Aktiv, ikke rekrutterende
- Lucas Research, Inc.
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Aktiv, ikke rekrutterende
- Childrens Hospital of Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37212
- Aktiv, ikke rekrutterende
- Vanderbilt Health One Hundred Oaks
-
-
Texas
-
Houston, Texas, Forenede Stater, 77065
- Aktiv, ikke rekrutterende
- Dynamed Clinical Research, LP d/b/a DM Clinical Research
-
Houston, Texas, Forenede Stater, 77071-1008
- Aktiv, ikke rekrutterende
- La Providence Pediatrics Clinic - Chemidox Clinical Trials
-
Tomball, Texas, Forenede Stater, 77375-3332
- Aktiv, ikke rekrutterende
- Martin Diagnostic Clinic
-
-
-
-
-
Beer Jacob, Israel, 73100
- Aktiv, ikke rekrutterende
- Shamir Medical Center
-
Jerusalem, Israel, 9013102
- Aktiv, ikke rekrutterende
- Shaare Zedek Medical Center
-
Ramat Gan, Israel, 52621
- Aktiv, ikke rekrutterende
- Sheba Medical Center
-
-
-
-
-
Florence, Italien, 50139
- Aktiv, ikke rekrutterende
- Azienda Ospedaliero Universitaria Meyer
-
Novara, Italien, 28100
- Aktiv, ikke rekrutterende
- Azienda Ospedaliero Universitaria Maggiore della Carità
-
Verona, Italien, 37126
- Aktiv, ikke rekrutterende
- Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento
-
-
-
-
-
Iruma-Gun, Japan, 350-0495
- Rekruttering
- Saitama Medical University Hospital
-
Kontakt:
- Telefonnummer: 81120023812
-
Ledende efterforsker:
- Toru Kikuchi
-
Isesaki-shi, Japan, 372-0817
- Rekruttering
- Isesaki Municipal Hospital
-
Kontakt:
- Telefonnummer: 81120023812
-
Ledende efterforsker:
- Yoko Takano
-
Kawaramachidori, Kamigyo-ku, Kyoto-city, Japan, 602-8566
- Ikke rekrutterer endnu
- University Hospital,Kyoto Prefectural University of Medicine
-
Kontakt:
- Telefonnummer: 81120023812
-
Ledende efterforsker:
- Satoru Sugimoto
-
Meguro-Ku, Japan, 152-0021
- Rekruttering
- Tokyo Medical Center
-
Kontakt:
- Telefonnummer: 81120023812
-
Ledende efterforsker:
- Masashi Miharu
-
Moriyama, Japan, 524-8524
- Rekruttering
- Shiga General Hospital
-
Kontakt:
- Telefonnummer: 81120023812
-
Ledende efterforsker:
- Katsuyuki Matsui
-
Nara, Japan, 630-8054
- Rekruttering
- Nara Prefecture General Medical Center
-
Kontakt:
- Telefonnummer: 81120023812
-
Ledende efterforsker:
- Sayaka Yoshida
-
Osaka, Japan, 534-0021
- Rekruttering
- Osaka City General Hospital
-
Kontakt:
- Telefonnummer: 81120023812
-
Ledende efterforsker:
- Jun Mori
-
Saga, Japan, 840-0801
- Rekruttering
- Sagaekiminami Clinic
-
Kontakt:
- Telefonnummer: 81120023812
-
Ledende efterforsker:
- Tateo Kuno
-
Zentsujichó, Japan, 765-8507
- Rekruttering
- Shikoku Medical Center for Children and Adults
-
Kontakt:
- Telefonnummer: 81120023812
-
Ledende efterforsker:
- Takafumi Okada
-
-
-
-
-
Krakow, Polen, 31-501
- Aktiv, ikke rekrutterende
- Krakowskie Centrum Medyczne - FutureMeds
-
Warsaw, Polen, 03-291
- Aktiv, ikke rekrutterende
- FutureMeds - Targowek
-
Warszewo, Polen, 2117
- Aktiv, ikke rekrutterende
- Instytut Diabetologii - Warsaw
-
Wroclaw, Polen, 53-673
- Aktiv, ikke rekrutterende
- FutureMeds sp. z o. o.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
J4M-MC-PWMP
-
Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.
-
Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart [CDC-NCHS, 2022]); OR
-
Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,
- hypertension
- type 2 diabetes (T2D)
- prediabetes
- dyslipidemia
- obstructive sleep apnea
- metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated steatotic liver disease (MASLD)
Exclusion Criteria:
J4M-MC-PW01
- Prepubertal (Tanner stage 1)
- Have a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kilograms (kg) (11 pounds) within 90 days before screening
J4M-MC-PWMP
-
Have undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:
- gastric bypass
- sleeve gastrectomy
- restrictive bariatric surgery, such as Lap-Band® gastric banding, or
- any other procedure intended to result in weight reduction.
-
Have a diagnosis that is a secondary cause of obesity or have a history of abrupt onset of obesity suggesting a secondary cause, such as hypothalamic, monogenetic, syndromic, or endocrine causes.
-
Have type 1 diabetes or history of ketoacidosis, or hyperosmolar state.
-
Have HbA1c >9.0% (75 mmol/mol) as measured by central laboratory at screening.
-
Have a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
Participants will receive placebo orally |
Administered orally |
|
Eksperimentel: Orforglipron
Participants will receive orforglipron orally |
Administered orally
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Procentvis ændring fra baseline i Body Mass Index (BMI)
Tidsramme: Baseline, uge 72
|
Baseline, uge 72
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Ændring fra baseline i kropsvægt
Tidsramme: Baseline, uge 72
|
Baseline, uge 72
|
|
|
Skift fra baseline i taljeomkreds
Tidsramme: Baseline, uge 72
|
Baseline, uge 72
|
|
|
Ændring fra baseline i systolisk blodtryk
Tidsramme: Baseline, uge 72
|
Baseline, uge 72
|
|
|
Ændring fra baseline i diastolisk blodtryk
Tidsramme: Baseline, uge 72
|
Baseline, uge 72
|
|
|
Procentvis ændring fra baseline i totalt kolesterol
Tidsramme: Baseline, uge 72
|
Baseline, uge 72
|
|
|
Ændring fra baseline i fastende glukose
Tidsramme: Baseline, uge 72
|
Baseline, uge 72
|
|
|
Ændring fra baseline i BMI
Tidsramme: Baseline, uge 72
|
Baseline, uge 72
|
|
|
Procent ændring fra baseline i fastende insulin
Tidsramme: Baseline, uge 72
|
Baseline, uge 72
|
|
|
Procent ændring fra baseline i total kropsfedtmasse som bestemt ved dobbelt-energi røntgenabsorption (DXA)
Tidsramme: Baseline, uge 72
|
Baseline, uge 72
|
|
|
Farmakokinetik (PK): Steady State areal under koncentrationstidskurven (AUC) for Orforglipron
Tidsramme: Baseline, uge 72
|
Baseline, uge 72
|
|
|
Change from Baseline in Body Weight Percentile
Tidsramme: Baseline, Week 72
|
Based on sex- and age-specific growth charts |
Baseline, Week 72
|
|
Change in Impact of Weight on Quality of Life (IWQOL)-Kids Total and Domain Scores
Tidsramme: Baseline, Week 72
|
The IWQOL-Kids is a validated, 27-item, patient reported outcomes instrument that assesses weight-related quality of life for youth aged 11 to 19 years in 4 domains:
|
Baseline, Week 72
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 18868
- J4M-MC-PW01 (Anden identifikator: Eli Lilly and Company)
- J4M-MC-PWMP Master Protocol (Anden identifikator: Eli Lilly and Company)
- 2024-514081-40-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD-delingstidsramme
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD-delingsadgangskriterier
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .